SEC Form 4 · accession 0001562180-18-004187
G1 Therapeutics, Inc. · GTHX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Terry L Murdock
Officer — SVP of Development Operations
Period of report
Oct 3, 2018
Accepted (ET)
Oct 5, 2018 · 6:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001560241
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 3, 2018 | M | 3,519 | $13.51 | A | 3,519 | D | |
| Common Stock | Oct 3, 2018 | S | 3,519 | $49.18 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to Buy)F2 | $13.51 | Oct 3, 2018 | M | 3,519 | D | — | Aug 1, 2027 | Common Stock | 3,519 | 89,443 | D |
Explanation of responses
- F1The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
- F2The shares underlying this option vested as to 25% of the shares on August 1, 2018, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.